Nectar Lifesciences Board Approves Q2 FY26 Results, Reports Significant Losses Amidst Business Divestment
Nectar Lifesciences' board approved Q2 FY26 standalone and consolidated results, reporting significant losses primarily from discontinued operations. The company completed the ₹127,398.55 lacs sale of its Pharma and Menthol businesses.
The impact is high due to the significant financial losses reported for both continuing and discontinued operations, coupled with the major strategic divestment of the Pharma and Menthol businesses, which fundamentally alters the company's structure and future revenue streams.
The company reported substantial total losses of -₹17,600.57 lacs for the quarter and -₹23,923.65 lacs for the half-year, primarily driven by massive losses from discontinued operations, which overshadows the completion of the business transfer.
* The Board of Directors of Nectar Lifesciences Limited, in their meeting held on November 14, 2025, approved the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025. * Standalone Financial Highlights for Q2 FY26 (Quarter Ended September 30, 2025): * Revenue from Operations: ₹499.66 lacs. * Total Income: ₹573.73 lacs. * Profit before tax from continuing operations: -₹50.62 lacs. * Profit before tax from discontinued operations: -₹27,001.61 lacs. * Total Profit for the period: -₹17,600.57 lacs. * Basic EPS (continuing & discontinued operations): -₹7.85. * Consolidated Financial Highlights for Q2 FY26 (Quarter Ended September 30, 2025): * Revenue from Operations: ₹499.66 lacs. * Total Income: ₹573.73 lacs. * Profit before tax from continuing operations: -₹50.62 lacs. * Profit before tax from discontinued operations: -₹27,001.61 lacs. * Total Profit for the period: -₹17,600.57 lacs. * Basic EPS (continuing & discontinued operations): -₹7.85. * The company undertook a major business transfer during the quarter: * On July 7, 2025, Nectar Lifesciences entered into a Business Transfer Agreement (BTA) to transfer its Active Pharmaceutical Ingredients (Pharma Business) to Ceph Lifesciences Private Limited via a slump sale for a consideration of ₹127,000 lacs. * Additionally, an Asset Purchase Agreement (APA) was signed on July 7, 2025, to transfer assets related to its menthol business to Ceph Lifesciences Private Limited for ₹2,000 lacs. * The proposed transfer, approved by shareholders on August 04, 2025, was completed on November 10, 2025. * The final consolidated consideration for both transfers, after working capital adjustments, was ₹127,398.55 lacs. * Consequently, assets and liabilities of the Pharma and Menthol businesses have been disclosed as
What to do with a filing like this
Nectar Lifesciences Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Nectar Lifesciences Limited. Read the original for the full detail.